Inflarx N.V. income statement

In fiscal 2025, Inflarx N.V. reported revenue of $33,162, down 81.5% on the year before and net income of −$51.6m, or −$0.77 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Inflarx N.V.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	0
Cost of revenue	1	4	8
Gross profit	−1	−3	−8
Research and development	44	38	29
Operating income	−49	—	—
Interest expense	0	0	0
Income before tax	−46	−50	−52
Income tax	—	0	0
Net income	−46	−50	−52
Diluted EPS	−$0.84	−$0.84	−$0.77
Diluted shares (average)	55m	59m	67m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IFRX vs LYEL AIM vs IFRX IBIO vs IFRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inflarx N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inflarx N.V.